Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Operating Expenses (2016 - 2025)

Cumberland Pharmaceuticals' Other Operating Expenses history spans 16 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 23.57% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $29.8 million, up 22.56%, while the annual FY2025 figure was $29.8 million, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $9.5 million at Cumberland Pharmaceuticals, up from $6.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $9.8 million in Q2 2024 and bottomed at $6.1 million in Q3 2021.
  • The 5-year median for Other Operating Expenses is $7.4 million (2021), against an average of $7.5 million.
  • The largest annual shift saw Other Operating Expenses surged 33.54% in 2024 before it dropped 26.23% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $7.6 million in 2021, then dropped by 15.17% to $6.5 million in 2022, then grew by 18.43% to $7.7 million in 2023, then dropped by 0.33% to $7.7 million in 2024, then rose by 23.57% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Other Operating Expenses are $9.5 million (Q4 2025), $6.4 million (Q3 2025), and $7.2 million (Q2 2025).